Professor — Status Only

Lawrence Alan Leiter

Department of Nutritional Sciences


St. Michael's Hospital
61 Queen Street East, 6th Floor, Toronto, Ontario Canada M5C 2T2
Research Interests
diabetes, atherosclerosis, lipids, hyperlipidemia, hypertension, obesity, clinical trials, dietary interventions
Appointment Status
Not accepting new students


  • Research Fellowship, Faculty of Medicine, University of Toronto (1980-1982)
  • Clinical Fellow, Endocrinology & Metabolism Program, University of Toronto (1979-1980)
  • Senior Assistant Resident, Internal Medicine, Toronto General Hospital (1978-1979)
  • Junior Assistant Resident, Internal Medicine, Toronto General Hospital (1977-1978)
  • Straight Intern, Internal Medicine, The Wellesley Hospital (1976-1977)
  • MDCM, McGill University (1976)
  • BSc (First Class Honours), Psychology, McGill University (1972)

Google Scholar

Other Academic and Clinical Appointments

Associate Scientist, Keenan Research Centre, Li Ka Shing Knowledge Institute (2008 - present)

Scientific Director, St. Michael’s Hospital, Canadian Cardiometabolic Risk Initiative (2007 - present)

Professor, Department of Nutritional Sciences, University of Toronto (1998- present)

Professor, Department of Medicine, University of Toronto (1998 - present)

Associate Director, Nutritional & Risk Factor Modification Centre, St. Michael’s Hospital (1990 - present)

Director, Lipid Clinic, St. Michael’s Hospital (1990 - present)

Associate Physician, Mount Sinai Hospital (1990 - present)

Staff Physician, St. Michael’s Hospital (1990 - present)

At a Glance

  • Dr. Leiter conducts clinical trials on the prevention of atherosclerosis, especially in diabetes
  • He also investigates dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity.
  • Dr. Leiter is an investigator in many of the landmark diabetes trials including the DCCT, ACCORD, and ADVANCE and is on the Executive/Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas.

About Dr. Lawrence Leiter

Dr. Lawrence A. Leiter is Director of the Lipid Clinic; Associate Director of the Clinical Nutrition and Risk Factor Modification Centre; and Associate Scientist, Li Ka Shing Knowledge Institute at St. Michael’s Hospital in Toronto where he was also the Head of the Division of Endocrinology and Metabolism from 2000-2010. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter is a Past-President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada. He is an Associate Editor of the journal Diabetes Care.

For his work, Dr. Leiter has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service, the 2005 CSEM Educator of the Year Award, and the 2006 CDA Gerald S. Wong Award in recognition of significant contributions to the diabetes community. He was the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009. He is also the 2016 recipient of both the CDA Lifetime Achievement Award for Research Excellence and the CSEM Robert Volpe Distinguished Service Award. In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences.

Research Synopsis

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 800 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the DCCT, ACCORD, and ADVANCE and has had leadership roles in many past and ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher.

Recent Awards and Distinctions (Selected)

Award for Top 1% Highly Cited Researchers, Clarivate Analytics (2020, 2019, 2018)

Research Laureate Award, American College of Physicians - Ontario Chapter (2020)

Fellow, Canadian Academy of Health Sciences (2019)

Fellow, American College of Cardiology (2018)

Lifetime Achievement Award for Research Excellence, Canadian Diabetes Association (2016)

Robert Volpe Distinguished Service Award, Canadian Society of Endocrinology and Metabolism (2016)

Charles H Best Lecture Award / U of T, Toronto Diabetes Association (2016)

Recent Publications

  1. Abtan J, Bhatt DL, Held C, Simon T, Fox K, Mehta SR, Harrington RA, Gao Q, Leiter LA, Steg PG. Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. Circ Cardiovasc Interv. 2021 Dec;14(12):e011035. doi: 10.1161/CIRCINTERVENTIONS.120.011035. Epub 2021 Nov 24. PMID: 34814698.
  2. Pitt B, Steg G, Leiter LA, Bhatt DL. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2021 Nov 9. doi: 10.1007/s10557-021-07291-y. Epub ahead of print. Erratum in: Cardiovasc Drugs Ther. 2021 Dec 24;: PMID: 34750713.
  3. Higgins V, Leiter LA, Delaney SR, Beriault DR. Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up? Clin Biochem. 2021 Oct 14:S0009-9120(21)00274-5. doi: 10.1016/j.clinbiochem.2021.10.003. Epub ahead of print. PMID: 34656564.
  4. Pieber TR, Bajaj HS, Heller SR, Jia T, Khunti K, Klonoff DC, Ladelund S, Leiter LA, Wagner L, Philis-Tsimikas A. Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial. Diabetes Obes Metab. 2021 Oct 4. doi: 10.1111/dom.14564. Epub ahead of print. PMID: 34605127.
  5. Berg DD, Wiviott SD, Scirica BM, Zelniker TA, Goodrich EL, Jarolim P, Mosenzon O, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Langkilde AM, Raz I, Braunwald E, Sabatine MS, Morrow DA. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care. 2021 Nov;44(11):2573-2581. doi: 10.2337/dc21-1170. Epub 2021 Sep 17. PMID: 34535469; PMCID: PMC8546278.
  6. Kosmopoulos A, Bhatt DL, Meglis G, Verma R, Pan Y, Quan A, Teoh H, Verma M, Jiao L, Wang R, Juliano RA, Kajil M, Kosiborod MN, Bari B, Berih AA, Aguilar M, Escano A, Leung A, Coelho I, Hibino M, Díaz R, Mason RP, Steg PG, Simon T, Go AS, Ambrosy AP, Choi R, Kushner AM, Leiter LA, Al-Omran M, Verma S, Mazer CD. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. iScience. 2021 Sep 24;24(9):103040. doi: 10.1016/j.isci.2021.103040. Epub 2021 Aug 26. PMID: 34462732; PMCID: PMC8388138.
  7. Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, Koenig W, Cannon CP, Budaj A, Hagström E, Siegbahn A, Wallentin L; STABILITY Investigators. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiol. 2021 Aug 25:e213079. doi: 10.1001/jamacardio.2021.3079. Epub ahead of print. PMID: 34431970; PMCID: PMC8387946.
  8. Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Park KS, Goudev A, Diaz R, Špinar J, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur Heart J. 2021 Aug 24:ehab530. doi: 10.1093/eurheartj/ehab530. Epub ahead of print. PMID: 34427295.
  9. Lo S, Leiter LA, Langer A, Tan M, Goldin L, Harris S, Yale JF, Ekoe JM, Lin PJ, Goodman SG, Yan AT. Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration? J Diabetes Complications. 2021 Oct;35(10):107997. doi: 10.1016/j.jdiacomp.2021.107997. Epub 2021 Jul 21. PMID: 34332851.
  10. Langer A, Mancini GBJ, Tan M, Goodman SG, Ahooja V, Grégoire J, Lin PJ, Stone JA, Leiter LA. Treatment Inertia in Patients With Familial Hypercholesterolemia. J Am Heart Assoc. 2021 Jul 20;10(14):e020126. doi: 10.1161/JAHA.120.020126. Epub 2021 Jul 9. PMID: 34238023; PMCID: PMC8483494.

National and International Committee Memberships (Current)

Member, Executive Committee VESALIUS Trial. Effect of Evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (2019 – present)

Member, Executive Committee SCORED Trial. Effect of Sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes and moderate renal impairment who are at cardiovascular risk (2017 – present)

Member, Executive Committee SOLOIST-WHF Trial. Effect of Sotagliflozin on cardiovascular events in patients with type 2 diabetes post worsening heart failure (2017 – present)

Member, Canadian Cardiovascular Society Lipid Guidelines (2015 – present)

Member, International Hypoglycemia Study Group (2012 – present)

Member, Canadian Harmonized Cardiovascular Risk Factor Management Guidelines (2009 – present)

Chair, Canadian Cardiometabolic Risk Working Group (2008 – present)

In the News

Inclisiran Lowers Cholesterol Across all BMI Groups. Physician’s Weekly. November 22, 2021.

Lawrence A. Leiter, MD: Inclisiran Lower Chosterol in Overweight Individuals. HCPLive. November 20, 2021.

Inclisiran Reduced LDL-C in Obese Patients. Diagnostic and Interventional Cardiology (DAIC). November 15, 2021.